Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. It acts as an anticonvulsant.
## Primary Indications
* Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS) in patients $\geq$ 2 years of age.
## Adult Dosing
* **Initiation:** Typically starts at 5 mg twice daily.
* **Titration:** Increase dose every week based on response and tolerability, not to exceed a target dose of 10 mg twice daily.
* **Maintenance:** Usual maintenance dose is 10 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 to less than 10 years of age)
* **Initiation:** Typically starts at 2.5 mg twice daily.
* **Titration:** Increase dose every week based on response and tolerability, not to exceed a target dose of 5 mg twice daily.
* **Maintenance:** Usual maintenance dose is 5 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg/day).
*Note: Dosing for pediatric patients 10 years of age and older but less than 30 kg should follow the pediatric dosing guidelines, while those $\geq$ 30 kg should follow adult dosing guidelines.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are provided, but initiation at the lower end of the dosing range and slower titration is recommended.
* **Renal Impairment:** Use with caution. No specific dose adjustments are provided, but initiation at the lower end of the dosing range and slower titration is recommended.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, fatigue, increased appetite, constipation, aggression, irritability, difficulty with coordination, rash, respiratory tract infections, upper respiratory tract infections, pneumonia.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms (paradoxical excitation, anxiety, insomnia, tremors, convulsions).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression, potentially leading to profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam plasma concentrations, increasing the risk of adverse effects.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam plasma concentrations, potentially reducing efficacy.
* **Anticonvulsants:** Clobazam can affect the pharmacokinetics of other anticonvulsants (e.g., increase levels of phenobarbital, primidone, phenytoin; decrease levels of valproic acid). Monitor anticonvulsant levels and adjust doses as needed.
## Monitoring
* **Efficacy:** Monitor seizure frequency and severity.
* **Tolerability:** Assess for CNS depressant effects (sedation, dizziness), behavioral changes, and rash.
* **Suicidal Ideation/Behavior:** Monitor for any worsening or emergence of suicidal thoughts or behaviors.
* **Withdrawal Symptoms:** Monitor for signs of withdrawal if discontinuing the medication.
* **Concomitant Anticonvulsant Levels:** Monitor levels of other antiepileptic drugs when initiating or discontinuing clobazam.
## Clinical Pearls
* Clobazam should be tapered slowly when discontinuing to avoid withdrawal symptoms.
* Due to the risk of severe skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
* A dose reduction may be necessary if used concomitantly with strong CYP3A4 inhibitors.
* Patients should be cautioned against operating heavy machinery or driving until they know how clobazam affects them.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details before making any treatment decisions.*
